Literature DB >> 29312476

Post-translational modifications of high mobility group box 1 and cancer.

Seidu A Richard1,2, Yuanyuan Jiang1, Lu Hong Xiang1, Shanshan Zhou1, Jia Wang1, Zhaoliang Su1,3, Huaxi Xu1.   

Abstract

Post-translational modifications (PTMs) of High mobility group box 1 (HMGB1) have not been investigated as extensively as those of other HMG proteins but accumulating evidence has shown the remarkable biological significances induced by the post-translational: acetylation, methylation and phosphorylation, oxidation, glycosylation and ADP-ribosylation of the HMGB1 to modulate its interactions with DNA and other proteins. Although HMGB1 is localized in the nucleus in almost all cells at baseline, it can be rapidly mobilized to other sites within the cell, including the cytoplasm and mitochondria, as well as into the extracellular; hence there is an increasing interest by researches into the complex relationship between the PTMs of HMGB1 protein and its diverse biological activities. The PTMs of HMGB1 could also have effects on gene expression following changes in its DNA-binding properties and in extracellular environment displays immunological activity and could serve as a potential target for new therapy. Our reviewed identifies covalent modifications of HMGB1, and highlighted how these PTMs affect the functions of HMGB1 protein in a variety of cellular and extra cellular processes as well as diseases and therapy.

Entities:  

Keywords:  HMGB1; autoimmune disease; cancer; modification; post-translational

Year:  2017        PMID: 29312476      PMCID: PMC5752874     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  120 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

Review 2.  New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal.

Authors:  S Müller; P Scaffidi; B Degryse; T Bonaldi; L Ronfani; A Agresti; M Beltrame; M E Bianchi
Journal:  EMBO J       Date:  2001-08-15       Impact factor: 11.598

3.  Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.

Authors:  A Taguchi; D C Blood; G del Toro; A Canet; D C Lee; W Qu; N Tanji; Y Lu; E Lalla; C Fu; M A Hofmann; T Kislinger; M Ingram; A Lu; H Tanaka; O Hori; S Ogawa; D M Stern; A M Schmidt
Journal:  Nature       Date:  2000-05-18       Impact factor: 49.962

4.  Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion.

Authors:  Tiziana Bonaldi; Fabio Talamo; Paola Scaffidi; Denise Ferrera; Annalisa Porto; Angela Bachi; Anna Rubartelli; Alessandra Agresti; Marco E Bianchi
Journal:  EMBO J       Date:  2003-10-15       Impact factor: 11.598

5.  Mitochondrial localization of non-histone protein HMGB1 during human endothelial cell-Toxoplasma gondii infection.

Authors:  Ana Carolina Stumbo; Erika Cortez; Carlos Alberto Rodrigues; Maria das Graças M O Henriques; Luís Cristóvão Porto; Helene S Barbosa; Laís Carvalho
Journal:  Cell Biol Int       Date:  2007-09-07       Impact factor: 3.612

6.  TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells.

Authors:  Deepak Mittal; Fabiana Saccheri; Emilie Vénéreau; Tobias Pusterla; Marco E Bianchi; Maria Rescigno
Journal:  EMBO J       Date:  2010-06-04       Impact factor: 11.598

7.  HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain.

Authors:  Jung-Bin Kim; Joon Sig Choi; Young-Mi Yu; Kihoon Nam; Chun-Shu Piao; Seung-Woo Kim; Min-Hyung Lee; Pyung-Lim Han; Jong-Sang Park; Ja-Kyeong Lee
Journal:  J Neurosci       Date:  2006-06-14       Impact factor: 6.167

8.  Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9.

Authors:  Terry K Means; Eicke Latz; Fumitaka Hayashi; Mandakolathur R Murali; Douglas T Golenbock; Andrew D Luster
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

9.  Stimulation of erythroleukaemia cell differentiation by extracellular high-mobility group-box protein 1 is independent of the receptor for advanced glycation end-products.

Authors:  Bianca Sparatore; Marco Pedrazzi; Mario Passalacqua; Deborah Gaggero; Mauro Patrone; Sandro Pontremoli; Edon Melloni
Journal:  Biochem J       Date:  2002-05-01       Impact factor: 3.857

10.  Natural Bcl-2 inhibitor (-)- gossypol induces protective autophagy via reactive oxygen species-high mobility group box 1 pathway in Burkitt lymphoma.

Authors:  Zhenhong Ni; Xufang Dai; Bin Wang; Wen Ding; Panke Cheng; Liang Xu; Jiqin Lian; Fengtian He
Journal:  Leuk Lymphoma       Date:  2013-03-13
View more
  18 in total

1.  [microRNA let-7g-3p regulates proliferation, migration, invasion and apoptosis of bladder cancer cells by targeting HMGB2].

Authors:  Z Zou; Q Cheng; Z Li; W Gao; W Sun; B Liu; Y Guo; J Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-09-20

Review 2.  Interactions of high mobility group box protein 1 (HMGB1) with nucleic acids: Implications in DNA repair and immune responses.

Authors:  Pooja Mandke; Karen M Vasquez
Journal:  DNA Repair (Amst)       Date:  2019-09-16

Review 3.  High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies.

Authors:  Shunling Yuan; Zhaoping Liu; Zhenru Xu; Jing Liu; Ji Zhang
Journal:  J Hematol Oncol       Date:  2020-07-13       Impact factor: 17.388

4.  Acetylation of HMGB1 by JNK1 Signaling Promotes LPS-Induced Peritoneal Mesothelial Cells Apoptosis.

Authors:  Shirong Cao; Shu Li; Yating Wang; Jiani Shen; Yi Zhou; Huiyan Li; Xueqing Yu; Haiping Mao
Journal:  Biomed Res Int       Date:  2018-11-12       Impact factor: 3.411

5.  Translationally controlled tumor protein affects colorectal cancer metastasis through the high mobility group box 1-dependent pathway.

Authors:  Maoliang Huang; Yan Geng; Qiaoting Deng; Ru Li; Xiangyang Shao; Zhigao Zhang; Weiwen Xu; Yingsong Wu; Qiang Ma
Journal:  Int J Oncol       Date:  2018-07-25       Impact factor: 5.650

6.  Overexpression of EPAC2 reduces the invasion of glioma cells via MMP-2.

Authors:  Ming Jiang; Yan Zhuang; Wang-Cun Zu; Lei Jiao; Seidu A Richard; Shiming Zhang
Journal:  Oncol Lett       Date:  2019-03-29       Impact factor: 2.967

Review 7.  HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma.

Authors:  Yanbin Wang; Zhaoqiang Jiang; Jianing Yan; Shibo Ying
Journal:  Dis Markers       Date:  2019-02-12       Impact factor: 3.434

8.  Ethyl pyruvate reduces organic dust-induced airway inflammation by targeting HMGB1-RAGE signaling.

Authors:  Sanjana Mahadev Bhat; Nyzil Massey; Locke A Karriker; Baljit Singh; Chandrashekhar Charavaryamath
Journal:  Respir Res       Date:  2019-02-06

Review 9.  Role of High-Mobility Group Box-1 in Liver Pathogenesis.

Authors:  Bilon Khambu; Shengmin Yan; Nazmul Huda; Xiao-Ming Yin
Journal:  Int J Mol Sci       Date:  2019-10-25       Impact factor: 5.923

Review 10.  Role of the NFκB-signaling pathway in cancer.

Authors:  Longzheng Xia; Shiming Tan; Yujuan Zhou; Jingguan Lin; Heran Wang; Linda Oyang; Yutong Tian; Lu Liu; Min Su; Hui Wang; Deliang Cao; Qianjin Liao
Journal:  Onco Targets Ther       Date:  2018-04-11       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.